General Information of Drug Metabolite (DM) (ID: DM001773)
DM Name
Salicylic acid
Synonyms
salicylic acid|2-Hydroxybenzoic acid|69-72-7|o-hydroxybenzoic acid|2-Carboxyphenol|o-Carboxyphenol|Rutranex|Salonil|Retarder W|Keralyt|Duoplant|Psoriacid-S-stift|Freezone|Saligel|Ionil|Stri-Dex|Verrugon|Salicylic acid collodion|Benzoic acid, 2-hydroxy-|Phenol-2-carboxylic acid|Salicylic acid soap|Acidum salicylicum|Trans-Ver-Sal|2-Hydroxybenzenecarboxylic acid|Orthohydroxybenzoic acid|Acido salicilico|Kyselina salicylova|Salicylic acid, tech.|Duofilm|Ionil-Plus|Dr. Scholl's callus removers|Clear away wart remover|Duofil wart remover|Domerine|Occlusal|Sebucare|Sebulex|Mediplast pads|Salicyclic acid|Akurza Lotion|Hydrisalic Gel|Kyselina 2-hydroxybenzoova|Akurza Cream|Ionil plus|Salex Lotion|Salex Cream|DuoPlant Gel|Caswell No. 731|Dr. Scholl's corn removers|Kyselina salicylova [Czech]|salicylicum acidum|DHS Sal Shampoo|P&S Shampoo|Dr. Scholl's wart remover kit|Durasal|Acido salicilico [Italian]|NSC 180|Advanced pain relief corn removers|Acido o-idrossibenzoico|2-hydroxy-benzoic acid|Acid, Salicylic|Kyselina 2-hydroxybenzoova [Czech]|Benzoic acid, hydroxy-|Advanced pain relief callus removers|CCRIS 6714|HSDB 672|ortho-Hydroxybenzoic Acid|Acido o-idrossibenzoico [Italian]|o Hydroxybenzoic Acid|Salicylic acid [USAN:JAN]|2 Hydroxybenzoic Acid|AI3-02407|Propa pH Peel-Off Acne Mask|Salicylic acid & Sulfur Soap|Acid, o-Hydroxybenzoic|Acid, 2-Hydroxybenzoic|EPA Pesticide Chemical Code 076602|CHEBI:16914|BRN 0774890|ortho Hydroxybenzoic Acid|NSC-180|Acid, ortho-Hydroxybenzoic|UNII-O414PZ4LPZ|EINECS 200-712-3|O414PZ4LPZ|MFCD00002439|Salicylic acid, tech|phenol derivative, 7|DTXSID7026368|FEMA NO. 3985|Salicylic acid (TN)|Bazuka Extra Strength Gel|CHEMBL424|Salicylic acid [USP:JAN]|Salicylic acid (6CI,8CI)|MLS000069653|DTXCID206368|NSC180|K 537|ATA fraction 10, ammonium salt|EC 200-712-3|CMC_13852|29656-58-4|NCGC00159447-05|SMR000059163|SAX|SALICYLIC ACID (MART.)|SALICYLIC ACID [MART.]|Salicylic acid-ring-UL-14C|E9A559BE-383B-4F83-BC02-3031D03D558A|SALICYLIC ACID (EP IMPURITY)|SALICYLIC ACID [EP IMPURITY]|SALICYLIC ACID (EP MONOGRAPH)|SALICYLIC ACID [EP MONOGRAPH]|Retarder SAX|SALICYLIC ACID (USP MONOGRAPH)|SALICYLIC ACID [USP MONOGRAPH]|C7H5O3|CAS-69-72-7|LAMIVUDINE IMPURITY C (EP IMPURITY)|LAMIVUDINE IMPURITY C [EP IMPURITY]|MESALAZINE IMPURITY H (EP IMPURITY)|MESALAZINE IMPURITY H [EP IMPURITY]|C7-H5-O3|2-hydroxy(1-14c)benzoic acid|NSC629474|SULFASALAZINE IMPURITY H (EP IMPURITY)|SULFASALAZINE IMPURITY H [EP IMPURITY]|ACETYLSALICYLIC ACID IMPURITY C (EP IMPURITY)|ACETYLSALICYLIC ACID IMPURITY C [EP IMPURITY]|SALICYLIC ACID, ACS|Benzoic acid, 2-hydroxy-, ion(1-) (9CI)|Azurechelin|Acnisal|salicylic-acid|salicylsyre-|Phenolic acid|Anti-blemish|Salicylic acid rs|Benzoic acid, 2-hydroxy-, coupled with 4-amino-5-hydroxy-2,7-naphthalenedisulfonic acid, diazotized 2,2'-(1,2-ethenediyl)bis(5-aminobenzenesulfonic acid) and diazotized 4-nitrobenzenamine, disodium salt|Benzoic acid, 2-hydroxy-, coupled with 4-amino-5-hydroxy-2,7-naphthalenedisulfonic acid, diazotized 2,2'-(1,2-ethenediyl)bis[5-aminobenzenesulfonic acid] and diazotized 4-nitrobenzenamine, disodium salt|hydroxy-benzoic acid|Fostex (Salt/Mix)|Pernox (Salt/Mix)|Duofilm Wart Remover|Phenol-2-carboxylate|Duofilm (Salt/Mix)|Salicylic Acid,(S)|Sebulex (Salt/Mix)|2-hydroxobenzoic acid|Domerine (Salt/Mix)|Sebucare (Salt/Mix)|2-Hydroxybenzoate, I|o-hydroxy benzoic acid|Salicylic Acid Reagent|2-hydroxy benzoic acid|Spectrum_000948|SLA (CHRIS Code)|Opera_ID_582|benzoic acid, 2 hydroxy|Salicylic acid ACS grade|WLN: QVR BQ|Benzoic acid, o-hydroxy-|2-Hydroxybenzenecarboxylate|bmse000252|C6H4(OH)COOH|D03RXH|D07HBX|Epitope ID:124929|Retarder SAX (Salt/Mix)|UPCMLD-DP126|SCHEMBL1967|SALICYLIC ACID [MI]|Oprea1_040343|KBioSS_001428|SALICYLIC ACID [JAN]|SALICYLIC ACID [USP]|BIDD:ER0602|DivK1c_000301|Salicylic acid (JP15/USP)|Salicylic acid (JP17/USP)|SALICYLIC ACID [HSDB]|SALICYLIC ACID [INCI]|SALICYLIC ACID [VANDF]|FEMA3985|GTPL4306|SGCUT00012|Salicylic acid, >=99%, FG|Salicylic acid, LR, >=99%|component of Tinver (Salt/Mix)|SALICYLIC ACID [USP-RS]|SALICYLIC ACID [WHO-DD]|SALICYLIC ACID [WHO-IP]|UPCMLD-DP126:001|BDBM26193|component of Keralyt (Salt/Mix)|KBio1_000301|KBio2_001428|KBio2_003996|KBio2_006564|Benzoic acid, 2-hydroxy-(9CI)|SALICYLICUM ACIDUM [HPUS]|NINDS_000301|HMS2233A10|HMS3373M19|HMS3885B08|KUC106694N|Salicylic acid, p.a., 99.0%|Benzoic acid, 2-hydroxy- (9CI)|BCP09067|HY-B0167|SALICYLIC ACID [GREEN BOOK]|to_000004|EINECS 305-634-4|EINECS 308-377-6|Lamivudine impurity, salicylic acid-|Tox21_113453|Tox21_201471|Tox21_303109|s4539|STK258681|2-HYDROXYBENZOIC ACID [FHFI]|AKOS000118979|Salicylic acid, BioXtra, >=99.0%|CCG-212792|CS-T-42070|DB00936|LS-2169|PB48023|IDI1_000301|SMP2_000145|NCGC00159447-01|NCGC00159447-02|NCGC00159447-04|NCGC00159447-06|NCGC00257065-01|NCGC00259022-01|94891-34-6|97952-82-4|ACIDUM SALICYLICUM [WHO-IP LATIN]|BP-12826|KSC-11-207-4|Salicylic acid & Sulfur Soap (Salt/Mix)|Salicylic acid, ACS reagent, >=99.0%|Salicylic acid, plant cell culture tested|Salicylic acid, ReagentPlus(R), >=99%|TS-03583|Salicylic Acid 1.0 mg/ml in Acetonitrile|SBI-0051510.P003|BENZOIC ACID,2-HYDROXY SALICYLIC ACID|FT-0645123|FT-0674502|FT-0674503|H0206|H1342|Salicylic acid, tested according to Ph.Eur.|EN300-16723|Salicylic acid, SAJ first grade, >=99.0%|C00805|D00097|D70842|Salicylic acid, Vetec(TM) reagent grade, 98%|AB00489876_15|BENZOIC ACID,2-HYDROXY SALICYLIC ACID|Salicylic acid, puriss. p.a., >=99.0% (T)|Q193572|CARBASALATE CALCIUM IMPURITY C [EP IMPURITY]|component of Solarcaine first aid spray (Salt/Mix)|J-509667|component of Fostex medicated bar and cream (Salt/Mix)|F2191-0216|DL-LYSINE ACETYLSALICYLATE IMPURITY A [EP IMPURITY]|Salicylic acid, certified reference material, TraceCERT(R)|Salicylic acid, British Pharmacopoeia (BP) Reference Standard|Salicylic acid, European Pharmacopoeia (EP) Reference Standard|Salicylic acid, United States Pharmacopeia (USP) Reference Standard|InChI=1/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10|Salicylic acid, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material|Salicylic acid, Pharmaceutical Secondary Standard; Certified Reference Material|8052-31-1
Structure
3D MOL 2D MOL
Pharmaceutical Properties Molecular Weight 138.12 Topological Polar Surface Area 57.5
Heavy Atom Count 10 Rotatable Bond Count 1
Hydrogen Bond Donor Count 2 Hydrogen Bond Acceptor Count 3
PubChem CID
338
Complexity
133
Formula
C7H6O3
Canonical SMILES
C1=CC=C(C(=C1)C(=O)O)O
InChI
InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)
InChIKey
YGSDEFSMJLZEOE-UHFFFAOYSA-N
IUPAC name
2-hydroxybenzoic acid
Toxicity Properties of This DM
Documented Toxicity Properties
Toxicity Class Toxic PMID: 24472429
Predicted Toxicity Properties
Physical and chemical properties LogP

The log of the n-octanol/water distribution coefficient.

LogP possess a leading position with considerable impact on both membrane permeability and hydrophobic binding to macromolecules. Therefore, LogP is widely used in drug discovery and development as an indicator of potential utility of a solute as a drug.

The predicted logP of a compound in the range from 0 to 3 log mol/L will be considered proper.

2.221 TPSA

Topological polar surface area

In TPSA, PSA is estimated only from the syntype (topology) of atoms in the molecule, without considering the three-dimensional structure of the molecule, which is the origin of the name topological polar surface area.

The TPSA of a compound in the range from 0 to 140 will be considered proper, based on Veber rule.

57.53
Pfizer Rule: Accepted

Molecules with a high log P (>3) and low TPSA (<75) are likely to be toxic.

Pfizer infered the relationship between the physicochemical properties and toxicity of the drug from an animal tolerability (IVT) study dataset of 245 preclinical Pfizer compounds.Compounds with a high log P (>3) and low TPSA ( <75) are likely to be toxic.

(Bioorg Med Chem Lett. 18(17):4872-5. 2008)

Structural Characteristics ALARM NMR Rule

Molecules containing the reactivity-related thiol substructures are likely to be toxic.

The high-throughput screening (HTS) hit rate of reactive compounds was evaluated by NMR screening, X-ray crystallography and other biochemical and biophysical experiments, and then 75 thiol substructures for predicting reactivity were obtained by computational means for 2348 screening hit reactive compounds and 1156 reactive compounds obtained by La protein experiments.The molecule was matched to 75 reactivity-related substructures to obtain the information how many alarm groups the molecule contained and determine whether it was a thiol-reactive compound. Molecules with the thiol substructures are likely to be toxic.

(J Am Chem Soc. 127(1):217-24. 2005)

1 PAINS

Molecules containing the reactive substructures are likely to be toxic.

Pan Assay Interference Compounds (PAINS) is one of the most famous frequent hitters filters, which comprises 480 substructures derived from the analysis of FHs determined by six target-based HTS assay. By application of these filters, it is easier to screen false positive hits and to flag suspicious compounds in screening databases. One of the most authoritative medicine magazines Journal of Medicinal Chemistry even requires authors to provide the screening results with the PAINS alerts of active compounds when submitting manuscripts.

(J Med Chem. 45(1):137-42. 2002)

0
BMS Rule

Molecules containing the reactivity-related substructures are likely to be toxic.

BMS's primary HTS data over the past 12 years was evaluated and analyzed to determine the correlation of a group of compound functional groups with Promiscuity, defined as a drug that acts with multiple molecular targets and exhibits different pharmacological effects.

(J Chem Inf Model. 46(3):1060-8. 2006)

0 Chelator Rule

Molecules containing the substructures associated with metalloprotease targeting are likely to be toxic.

The chelate substructure fragment library (eCFL) for targeting metalloproteinases was prepared and its effectiveness in screening metalloproteinase inhibitors was verified by analysis and fluorescence-based assay experiments, and 55 substructures associated with metalloprotease targeting were finally determined as alert structures.

(ChemMedChem. 5(2):195-9. 2010)

1
Genotoxic Carcinogenicity Rule

Molecules containing the Genotoxic substructures are likely to be carcinogenic.

By constructing a molecular structure dataset containing the corresponding Ames test data (mutagens and non-mutagens). The substructure of the dataset is searched, and then the toxic substructure obtained by using chemical and mechanical knowledge and statistical criteria is derived, and the new toxic substructure is obtained and approved, and finally the reliability of the verification set is verified. Molecules containing these substructures may cause carcinogenicity or mutagenicity through genotoxic mechanisms.There are 117 substructures in this endpoint.

(J Med Chem. 48(1):312-20. 2005)

0 Non-genotoxic Carcinogenicity Rule

Molecules containing the NonGenotoxic substructures are likely to be carcinogenic.

Through the analysis and verification of the existing molecular library or the molecular library mined by data, the list of non-gene carcinogenic substructures (SA) is obtained according to the computerized data mining analysis, and finally the reliability of the substructure is verified. Molecules containing these substructures may cause carcinogenicity through nongenotoxic mechanisms. There are 23 substructures in this endpoint.

(Mutat Res. 659(3):248-61. 2008)

0
Toxicity Model Prediction hERG Blockers

The possibility of causing cardiotoxicity.

The human ether-a-go-go related gene. The During cardiac depolarization and repolarization, a voltage-gated potassium channel encoded by hERG plays a major role in the regulation of the exchange of cardiac action potential and resting potential. The hERG blockade may cause long QT syndrome (LQTS), arrhythmia, and Torsade de Pointes (TdP), which lead to palpitations, fainting, or even sudden death.So build a model by collecting a dataset to predict whether a compound is a hERG Blocker.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.048 (---) H-HT

The possibility of causing .hepatotoxicity.

The human hepatotoxicity. Drug induced liver injury is of great concern for patient safety and a major cause for drug withdrawal from the market. Adverse hepatic effects in clinical trials often lead to a late and costly termination of drug development programs.So build a model by collecting datasets to predict whether compounds will cause hepatotoxicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.594 (+)
DILI

The possibility of causing liver injury.

Drug-induced liver injury (DILI) has become the most common safety problem of drug withdrawal from the market over the past 50 years.So build a model by collecting datasets to predict whether compounds will cause liver injury.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.856 (++) CAMES Toxicity

The possibility of causing mutagenicity.

The Ames test for mutagenicity. The mutagenic effect has a close relationship with the carcinogenicity, and it is the most widely used assay for testing the mutagenicity of compounds.So build a model by collecting datasets to predict whether compounds will cause mutagenicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.018 (---)
Carcinogencity

The possibility of causing Carcinogencity.

Among various toxicological endpoints of chemical substances, carcinogenicity is of great concern because of its serious effects on human health. The carcinogenic mechanism of chemicals may be due to their ability to damage the genome or disrupt cellular metabolic processes. Many approved drugs have been identified as carcinogens in humans or animals and have been withdrawn from the market.So build a model by collecting datasets to predict whether compounds will cause Carcinogencity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.046 (---) Respiratory Toxicity

The possibility of causing Respiratory Toxicity.

Among these safety issues, respiratory toxicity has become the main cause of drug withdrawal. Drug-induced respiratory toxicity is usually underdiagnosed because it may not have distinct early signs or symptoms in common medications and can occur with significant morbidity and mortality.Therefore, careful surveillance and treatment of respiratory toxicity is of great importance.So build a model by collecting datasets to predict whether compounds will cause Respiratory Toxicity.

The output value is the probability of being toxic, within the range of 0 to 1. 0-0.3: excellent; 0.3-0.7: medium; 0.7-1.0: poor.

(Brief Bioinform. 22(3):bbaa194. 2021)

0.897 (++)
Full List of Drug-Metabolizing Enzyme (DME) Related to This DM
DME(s) Producing This DM through Metabolism
DME Name DME ID Reactant Reaction Related Drug REF
Carboxylesterase 2 (CES2) DME0057 Unclear - Unclear Aspirin [1]
Esterases (ES) DMEN229 Unclear - Unclear Salsalate [2]
DME(s) Metabolizing This DM
DME Name DME ID Product Reaction Related Drug REF
Cytochrome P450 2C9 (CYP2C9) DME0019 Unclear - Unclear Aspirin [1]
UDP-glucuronosyltransferase 1A6 (UGT1A6) DME0072 Conjugation - Glucuronidation Aspirin [1]
UDP-glucuronosyltransferase 1A6 (UGT1A6) DME0072 Conjugation - Glucuronidation Aspirin [1]
Full List of Drug(s) That Produce This DM By Metabolism
Aspirin DR1749 Approved Myocardial infarction
Benzoic acid DR5271 Approved Fungal infection
Salsalate DR5251 Approved Rheumatoid arthritis
NCX-4016 DR3242 Phase 2 Inflammation
Salicin DR2482 Investigative Anaesthesia
References
1 Effect of common single-nucleotide polymorphisms in acetylsalicylic acid metabolic pathway genes on platelet reactivity in patients with diabetes Med Sci Monit. 2013 May 27;19:394-408. doi: 10.12659/MSM.883922.
2 AMPK: mediating the metabolic effects of salicylate-based drugs?

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.